The current work is the first to demonstrate that vaccination with an engineered picornavirus expressing tumor-specific antigen is effective at delaying GL261 glioma progression and extending survival, and that these effects are dependent upon increased CNS-infiltrating cytotoxic CD8+ T cells recognizing the tumor antigen. This evidence concerns the gene CD8A and glioma.